Johnson & Johnson Private Limited is partnering with the Institute of Microbial Technology (IMTECH), to accelerate R&D for innovative new treatments for tuberculosis (TB) in India – a hotbed for the killer infectious disease. IMTECH is a research institute of India’s Council of Scientific and Industrial Research (CSIR).
The partners expect to explore “more effective, safer, all-oral treatment regimens” for multidrug-resistant TB (MDR-TB) and also develop new molecular...







